Skip to content

Effectiveness of a REhabilitationprogram to treat fatigue in patients who suffered from a SubArachnoid Haemorrhage (RE-SAB); a pilot study

Effectiveness of a REhabilitationprogram to treat fatigue in patients who suffered from a SubArachnoid Haemorrhage (RE-SAB); a pilot study - RE-SAB

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON48074
Enrollment
20
Registered
2019-07-29
Start date
2019-10-14
Completion date
Unknown
Last updated
2025-03-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cerebral haemorrhage subarachnoid haemorrhage

Interventions

The intervention will last 6 months en consists of 24 times fitness training, 6 coach sessions and 3 information sessions. In the first period of 3 months, the patient will perform the fitness train

Sponsors

Erasmus MC, Universitair Medisch Centrum Rotterdam
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Admitted and treated/controlled at the neurology or neurosurgery department of Erasmus MC; - Diagnosed with a subarachnoid haemorrhage (SAH) by computed tomography or if negative, by a lumbar puncture; - Experience fatigue symptoms; - At least 18 years of age; - Living at home.

Exclusion criteria

Exclusion criteria: - > 2 years post SAH onset; - Traumatic SAH; - Previous stroke; - Serious chronic disease (including neurological diseases); - Insufficient mastery of the Dutch language; - Inability to understand verbal instructions and/or fill in the questionnaires (clinical judgement by neurologist).

Design outcomes

Primary

MeasureTime frame
Fatigue and Quality of Life

Secondary

MeasureTime frame
Self-efficacy, mood, cognition, coping style, (social) participation, illness perception, therapy expectancy, physical fitness, physical activity, patient satisfaction and practical feasibility.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)